Evidence Level
Phosphatidylcholine has a strong evidence base supporting its role in liver health and other therapeutic areas. Lieber et al. (1990) demonstrated that polyunsaturated phosphatidylcholine (PPC) mitigated alcohol-induced hepatic fibrosis in baboons. In a large-scale study, Lieber et al. (2003) evaluated PPC in 789 patients with alcoholic liver disease over two years, noting trends toward reduced fibrosis despite high dropout rates. Gundermann et al. (2016) conducted a comprehensive review of 85 clinical studies involving over 6,000 patients with non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD), finding consistent improvements in liver enzymes and imaging outcomes.
Recent research has expanded phosphatidylcholine's applications. Stremmel et al. (2021, 2022) conducted meta-analyses of three randomized controlled trials involving 160 ulcerative colitis patients, showing that enteric lecithin with phosphatidylcholine significantly improved remission rates and clinical outcomes compared to placebo. Additionally, Li et al. (2025) used Mendelian randomization to demonstrate that omega-3 fatty acids reduce multiple myeloma risk through a mechanism involving phosphatidylcholine.
Phosphatidylcholine is widely prescribed as a hepatoprotective agent, particularly in Europe and Asia, with formulations like Essentiale being commonly used. These studies underscore its potential benefits across various health conditions.